Y-mAbs Therapeutics, Inc. Profile Avatar - Palmy Investing

Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal anti…

Biotechnology
US, New York [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

Y-mAbs Therapeutics, Inc. has no acquisition track records yet.

M&A Deals · History

Y-mAbs Therapeutics, Inc. has no acquisition track records yet.

End of YMAB's Analysis
CIK: 1722964 CUSIP: 984241109 ISIN: US9842411095 LEI: - UEI: -
Secondary Listings
YMAB has no secondary listings inside our databases.